Sermorelin
A synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) used in research on GH deficiency, aging, and metabolic function.
Mechanism of Action
Sermorelin is the biologically active fragment of GHRH (amino acids 1-29). It binds to GHRH receptors on anterior pituitary somatotrophs, stimulating natural GH synthesis and release in a physiological pulsatile pattern. Unlike exogenous GH, it preserves the negative feedback loop and does not suppress endogenous GH production.
Key Published Studies
Clinical Studies with Sermorelin: A Growth Hormone-Releasing Hormone Analogue
Walker RF, Codd EE, Baird FC, Perrin CL — Hormone Research (1990)
Sermorelin produced sustained increases in endogenous GH secretion and IGF-1 levels in GH-deficient subjects with preserved pituitary function.
Effects of Six Months of Sermorelin Therapy on Sleep Quality and GH Secretion in the Elderly
Vittone J, Blackman MR, Busby-Whitehead J, et al. — Journal of Clinical Endocrinology and Metabolism (1997)
Sermorelin administration improved GH secretion patterns and increased slow-wave sleep duration in elderly subjects over 6 months.
Dosage Range
Subcutaneous research doses: 100-300 mcg before bed. Often combined with GHRP-2 or GHRP-6.
Reconstitution
Reconstitute with bacteriostatic water. For a 2 mg vial, add 2 mL BAC water for 1 mg/mL.
Storage
Store lyophilized at -20C. Reconstituted at 2-8C, use within 14 days. Sermorelin is relatively fragile.
Half-Life
Approximately 10-20 minutes. Administered before bed to coincide with natural GH pulse timing.
Related Products
For Research Use Only. The information on this page is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. All products sold by PrestigePeptides are strictly for laboratory research use and are not intended for human or veterinary consumption.
Ready to start your research?